Arrowhead Pharmaceuticals, Inc. (ARWR)

Arrowhead Pharmaceuticals Stock Forecast

Stock Price Forecast

The 10 analysts that cover Arrowhead Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $81.5, which forecasts a 23.32% increase in the stock price over the next year. The lowest target is $17 and the highest is $110.

Price Target: $81.5 (+23.32%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$17	$81.5	$81	$110
Change	-74.28%	+23.32%	+22.56%	+66.44%

Analyst Ratings

The average analyst rating for Arrowhead Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Sep '25	Oct '25	Nov '25	Dec '25	Jan '26	Feb '26
Strong Buy	4	4	4	5	6	5
Buy	3	2	2	2	2	2
Hold	2	2	4	3	3	3
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	9	8	10	10	11	10

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Patrick R. Trucchio HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Reiterates $100	Strong Buy	Reiterates	$100	+51.31%	Feb 10, 2026
Madison El-Saadi B. Riley Securities	B. Riley Securities	Strong Buy Maintains $61 → $101	Strong Buy	Maintains	$61 → $101	+52.82%	Jan 22, 2026
Patrick R. Trucchio HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Maintains $85 → $100	Strong Buy	Maintains	$85 → $100	+51.31%	Jan 21, 2026
Edward Tenthoff Piper Sandler	Piper Sandler	Buy Reiterates $100 → $110	Buy	Reiterates	$100 → $110	+66.44%	Jan 13, 2026
Andrea Tan Goldman Sachs	Goldman Sachs	Hold Maintains $50 → $85	Hold	Maintains	$50 → $85	+28.61%	Jan 7, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

423.11M

Decreased by -48.99%

from 829.45M

Revenue Next Year

327.83M

Decreased by -22.52%

from 423.11M

EPS This Year

-3.44

from -0.01

EPS Next Year

-4.64

from -3.44

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Sep 30, 2021	Sep 30, 2022	Sep 30, 2023	Sep 30, 2024	Sep 30, 2025	Sep 30, 2026	Sep 30, 2027
Revenue	138.29M	243.23M	240.74M	3.55M	829.45M	423.11M	327.83M
Revenue Growth	57.16%	75.89%	-1.03%	-98.53%	23,258.15%	-48.99%	-22.52%
EPS	-1.36	-1.67	-1.92	-5.00	-0.01	-3.44	-4.64
EPS Growth	-	-	-	-	-	-	-
Forward PE	-	-	-	-	-	-	-
No. Analysts	-	-	-	-	-	15	13

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2026	2027	2028	2029	2030
High	672.0M	501.9M
Avg	423.1M	327.8M
Low	98.0M	111.9M

Revenue Growth

Revenue Growth	2026	2027	2028	2029	2030
High	-19.0%	18.6%
Avg	-49.0%	-22.5%
Low	-88.2%	-73.5%

EPS Forecast

EPS	2026	2027	2028	2029	2030
High	-2.13	-2.73
Avg	-3.44	-4.64
Low	-5.81	-6.63

EPS Growth

EPS Growth	2026	2027	2028	2029	2030
High	-	-
Avg	-	-
Low	-	-

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.